Microcoaxial torsional phaco method of choice

Article

The vast majority of ophthalmologists are going to become convinced that 2.2 mm microcoaxial surgery with Ozil (Alcon) phaco must be the method of choice for both surgeons and patients said Dr Robert Osher.

The vast majority of ophthalmologists are going to become convinced that 2.2 mm microcoaxial surgery with Ozil (Alcon) phaco must be the method of choice for both surgeons and patients said Dr Robert Osher.

Dr Osher, who is working with a new proprietary Ozil programme, told delegates that there is very little turbulence with the Ozil. "There is an enormous amount of efficiency and it is thermal protected. Not only is there additional thermal protection for the sleeve but, because of the slope of the tip, there's 20% less temperature in the incision."

Again, Dr Osher was discussing a proprietary tip that is due to become available shortly. "Normally I prefer a straight tip, but I've switched to this because the torsional technique needs some slope and it reduces temperatures."

He noted that there is no learning curve with microcoaxial phaco, however there is a learning curve for lens injection. "Once you learn the technique it is incredibly safe, effective and reliable," he said.

"It takes faith to get a lens through an un-enlarged 2.2 mm incision, but they offer stable chambers and reduction of turbulence that convinces me that this is the best operation available for my patients."

To prove his point, Dr Osher showed a video procedure of a patient with segmental iris dysgenesis. "There's no stroma, only pure pigment, which will be liberated in the chamber if there's any turbulence at all, and as you can see, there's no pigment liberated. What better demonstration of the gentleness of this procedure."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.